Emerging Markets

December 2011

Non-Small-Cell Lung Cancer in Russia

Report Authors
Natalia Reoutova, M.A., M.Sc.
Alison Isherwood, M.Sc., Ph.D.

Introduction:

The incidence of non-small-cell lung cancer (NSCLC) in Russia is the highest among the BRIC (Brazil, Russia, India, China) markets, and is comparable to that of the United Kingdom and the United States. Increasing risk of non-small-cell lung cancer due to increasing smoking prevalence, in conjunction with an aging population, will drive an increase in incident non-small-cell lung cancer cases in Russia through 2020. In this report, we examine the trends within Russia’s NSCLC therapy market, which is characterized by the growing incident population, gradually increasing use of higher-priced chemotherapies and the introduction of several premium-priced agents.

Questions Answered in This Report:

  *   Incidence of NSCLC in Russia is the highest in BRIC markets and is comparable to that of the United Kingdom and the United States.  How does incidence of NSCLC translate into drug-treated NSCLC cases in Russia? Will population dynamics and rates of treatment across all stages of NSCLC sustain commercial opportunity in Russia through 2015?

  *   Reimbursement policies in both the public and private sectors are a major factor influencing expenditure on NSCLC treatments in Russia. Which groups of Russian patients are eligible for government-reimbursed treatment of NSCLC? What types of treatment are included in the Additional Drug Coverage? Which therapies are not readily reimbursed to the Russian patients by the government and what are the current patient shares of those therapies?

  *   In 2010, the most commonly prescribed agents for the treatment of NSCLC were different in Russia to those most commonly prescribed in the major markets for the same indication. What are the most-prescribed regimens for the treatment of NSCLC in Russia, across all stages? How much influence does histology type have on Russian physicians’ prescription choices? How do molecular testing practices vary between Russia and the major markets, in the context of NSCLC?

Scope:

Primary research: 90 oncologists surveyed across Russia (including 60 oncologists surveyed in four major cities [Moscow, Saint Petersburg, Novosibirsk, and Ekaterinburg]). Separate in-depth interviews with 8 Russian oncologists.

Epidemiology: Total incident cases of NSCLC in Russia over a ten-year period (2010-2020) by age, by gender, by histology, by Federal District, and by major city.

Current therapies and medical practice: Reporting use of brands and generics for the NSCLC treatments available in Russia.

Pricing and reimbursement: Prices of NSCLC therapies in Russia versus other major markets and analysis of the impact of government reimbursement on treatment trends.

Market forecast features: Our analysis evaluates rates of NSCLC progression and rates of drug treatment with NSCLC therapies, across all stages of the disease. We include a detailed forecast of current and emerging therapies within platinum agents, taxanes, antimetabolites, vinca alkaloids, topoisomerase II inhibitors, DNA-interacting agents, VEGF/EGFR monoclonal antibodies, kinase inhibitors, and PARP inhibitors classes of drugs, from 2010 through 2015, using a combination of historical trend analysis and an epidemiology-based, bottom-up market model.


Search Reports

Mentioned in this report:

  • - Abbott
  • - Agennix
  • - Amgen
  • - ArQule
  • - AstraZeneca
  • - Baxter
  • - Bayer
  • - Biokad
  • - BioNumerik
  • - BiPar Sciences
  • - Boehringer Ingelheim
  • - Bristol-Myers Squibb
  • - Celgene
  • - Cerulean
  • - Chugai
  • - Daiichi Sankyo
  • - Eli Lilly
  • - Farmstandart
  • - Genentech
  • - GlaxoSmithKline
  • - ImClone
  • - Kyowa Hakko Kirin
  • - Merck Serono
  • - Oncothyreon
  • - OSI Pharmaceuticals
  • - Peregrine
  • - Pfizer
  • - Pierre Fabre
  • - Roche
  • - Sanofi
  • - Soteks
  • - Takeda
  • - Wyeth
Decision Resources Group brands include: